Mission
By introducing the Open Innovation system,
HLB is growing into a global anticancer company based on a variety of new anticancer drugs licensed
through worldwide network.
Under the mid-term vision of 'a grand goal,
and its beginning', we are developing the best-in-class targeted anticancer drug 'Rivoceranib', along with the next-generation immunotherapy vaccine platform, 'UNITE', designed for various conditions including cancer and allergies. Our aim is to launch over 5 anticancer drugs by 2025, bringing us closer to realizing ‘Human Life Better’.
Established in 1975, HLB's corporate history reflects the essence of Korea's manufacturing industry.
Beginning as a modest lifeboat manufacturing company situated on a remote beach in Ulsan,
we expanded into shipbuilding and the production of fiberglass pipes, exporting our products worldwide.
Now, after a decade of hard work, we are on the verge of emerging as a global leader
in pharmaceuticals and biotechnology.
We've grown, but did not settle down, and when we fell, we got up and took a bigger step forward.
The spirit of challenge and passion over the past 40 years have been engraved
in our hearts as an entrepreneurial spirit called ‘DNA of overcoming and breakthrough.’
Armed with practical business ethics and a strong entrepreneurial spirit,
we continually push beyond our limitations. Together, we strive to turn our collective dreams into reality,
igniting a fire in our hearts.
As we approach our 50th anniversary, we invite you to join us as partners on this exciting journey.
